Cell News and Research

RSS

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

17 Sep 2009

Seegene awarded patent in the U.S. and Europe for Annealing Control Primer

Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded patent in the U.S. and Europe for Annealing Control Primer (ACP), a new technology for amplifying a specific region of a gene with much higher specificity and reproducibility than conventional approaches.

17 Sep 2009

Guide reveals that non-smokers require different treatment for lung cancer

A committee of scientists led by Johns Hopkins investigators has published a new guide to the biology, diagnosis and treatment of lung cancer in never-smokers, fortifying measures for what physicians have long known is a very different disease than in smokers.

17 Sep 2009

Link between a key molecular player and human chromosomal birth defects established

Using yeast genetics and a novel scheme to selectively remove a single protein from the cell division process called meiosis, a cell biologist at The Florida State University found that when a key molecular player known as Pds5 goes missing, chromosomes fail to segregate and pair up properly, and birth defects such as Down syndrome can result.

17 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Successful eye surgery involves eyetooth implant in eye

Blind for nine years, Sharron “Kay” Thornton has just regained her sight through a first-in-the-U.S. surgical procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The procedure -- modified osteo-odonto-keratoprosthesis (MOOKP) -- implanted her eyetooth in her eye, as a base to hold a prosthetic lens.

17 Sep 2009

Clinical trial focuses on healing diabetic foot ulcers with stem cells

Fortis Healthcare, one of India's leading private hospital groups, has announced it will broaden inclusion criteria for its upcoming diabetic foot clinical trial. The study will use stem cells derived from peripheral blood to treat critical limb ischemia (diabetic foot).

17 Sep 2009

Bioheart's MARVEL Phase II/III clinical trial successful

Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.

17 Sep 2009

Green tea may help prevent cancer and bone loss

Researchers in Hong Kong are reporting new evidence that green tea - one of the most popular beverages consumed worldwide and now available as a dietary supplement - may help improve bone health.

17 Sep 2009

Researchers discover HIV Nef protein's role in cell mobility inhibition

In order to be able to ward off disease pathogens, immune cells must be mobile and be able to establish contact with each other. The working group around Professor Dr. Oliver Fackler in the Virology Department of the Hygiene Institute of the Heidelberg University Hospital has discovered a mechanism in an animal model revealing how HIV, the AIDS pathogen, cripples immune cells: Cell mobility is inhibited by the HIV Nef protein.

17 Sep 2009

New technique found that may prevent vision loss

Blocking a protein that battles infection may help thwart a common cause of vision loss in chronic diseases such as diabetes, Medical College of Georgia researchers say.

16 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Cyntellect announces commercial availability of Stem Cell Manager

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of Stem Cell Manager powered by LEAP.

16 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

16 Sep 2009

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

16 Sep 2009

Poniard Pharmaceuticals to present its corporate overview

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 2009 UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 3:00 p.m. Eastern Time at the Grand Hyatt Hotel in New York City.

16 Sep 2009

Children's Hospital enrolls patients for ExCell clinical study

Children's Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children's Hospital is enrolling patients for the ExCell study. Children's Hospital is the 24th in a series of cord blood transplant sites worldwide, five of which are children's centers, participating in the study in the U.S., Spain, Italy, Hungary and Israel.

16 Sep 2009

Applied Biosystems launches MeltDoctor High-Resolution Melt Reagents for scanning DNA

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the launch of genomic analysis tools that will help researchers in studies that associate genetic variation with specific diseases. These new tools, known as the MeltDoctor™ High-Resolution Melt (HRM) Reagents, are for research use only and are part of a PCR-based workflow that enables researchers to cost-effectively scan DNA from a variety of biological sample types to detect the smallest genetic variations among samples.

16 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009